removal of the N-terminal glycopeptide.
The mechanism of activation of human Factor X, however, has been much less investigated. Di Scipio et al. (1977b) described the activation of Factor X by the Factor X-activating proteinase from Russell's-viper venom. Their results showed the presence of two sites of cleavage on the heavy chain of human Factor X, suggesting a close resemblance between the mechanisms of activation of human and bovine Factor X.
In this paper we report our investigations on the molecular events that occur during the activation of human Factor X by Russell's-viper venom and by the purified physiological activators involved in the intrinsic and extrinsic pathway. Conversion of Factor X was followed by amidolytic assays and SDS/polyacrylamide-gel electrophoresis. The results demonstrate the presence of three sites of cleavage on the heavy chain of human Factor X. The cleavage at one of these sites is responsible for the removal of the active-site serine residue from the Factor X molecule.
Experimental
Materials DEAE-Sephadex A-50, Sephadex G-75, Sepharose 4B and CNBr-activated Sepharose 4B were products of Pharmacia Fine Chemicals, Uppsala, 0306-3275/80/030647-12 $1.50/1 Sweden. Heparin was purchased from Organon, Oss, The Netherlands. Trasylol (aprotinin) and benzamidine hydrochloride were products of Bayer, Leverkusen, West Germany, and Aldrich Europe, Beerse, Belgium respectively. Hirudin, soya-bean trypsin inhibitor, Echis carinatus venom, L-a-phosphatidyl-L-serine and L-a-phosphatidylcholine (type I-H) were obtained from Sigma Chemical Co., St. Louis, MO, U.S.A. SDS, acrylamide and dithiothreitol were purchased from Bio-Rad Laboratories, Richmond, CA, U.S.A.; NN'-methylenebisacrylamide was from Merck-Schuchart, Hohenbrunn, West Germany; Coomassie Brilliant Blue R250 was from Serva, Heidelberg, West Germany; molecularweight markers (range 14 300-71 500) were from BDH Chemicals, Poole, Dorset, U.K. NNN'N'-Tetramethylethylenediamine and Dip-F were products of Koch-Light Laboratories, Colnbrook, Bucks., U.K.
[3H]Dip-F (specific radioactivity 3.0 Ci/mmol) was obtained from The Radiochemical Centre, Amersham, Bucks., U.K. Russell's-viper venom was obtained from Wellcome Reagents, Beckenham, Kent, U.K. Compounds S-2222 (N-Bz-Ile-Glu-Gly-Arg-p-nitroanilide hydrochloride) and S-2238 (H-D-Phe-Pip-Arg-p-nitroanilide dihydrochloride) were products of Kabi Diagnostica, Stockholm, Sweden. All other chemicals were analytical-grade products from Merck, Darmstadt, West Germany or BDH Chemicals.
Heparin-Sepharose type I was prepared as described by Andersson et al. (1975) (heparin and CNBr were added simultaneously to the Sepharose 4B). Heparin-Sepharose type II was prepared by coupling heparin to CNBr-activated Sepharose 4B (20 mg/g of activated Sepharose) by following the instructions of the manufacturers. This method was also used for coupling Russell's-viper venom to Sepharose 4B (2 mg/g of activated Sepharose). Analytical methods Assaysfor coagulationfactors. Factor IX activity was assayed as a kaolin-activated partial thromboplastin time in plasma of a patient with severe Factor IX deficiency (Veltkamp et al., 1968) . Activities of Factors II, VII and X were determined in onestage assays (with human brain thromboplastin as the activator) by using artificially depleted reagents prepared as described by Koller et al. (1951) , and Hemker et al. (1972) . Very low concentrations of Factor II were assayed by activating it with E. carinatus venom and measuring the released thrombin by its amidolytic activity towards the chromogenic peptide substrate S-2238 (Bertina et al., 1979) . Factor X antigen was measured in an electroimmunoassay, by using a specific rabbit anti-(human Factor X) serum, essentially as described for Factor IX by Bertina & Van der Linden (1977) . One unit of coagulant activity or antigen equals the amount of activity or antigen present in lml of pooled normal plasma. Amidolytic assays for Factor Xa and Factor X were performed by using the chromogenic substrate S-2222, by modifications of the methods of Aurell et al. (1977) and Bergstr6m & Egberg (1978) (1 unit/ml) equals 3.1 nkat/ml. SDS/polyacrylamide-gel electrophoresis. This was performed by the method described by Weber & Osborn (1969) . Unless stated otherwise, the gels were 7.5% (w/v) in acrylamide. Samples (approx. 10,ug of protein) were prepared for electrophoresis by incubation for 1 h at 560C in the presence of 4.3 M-urea, 1% (w/v) SDS and, when samples had to be reduced, 20 mM-dithiothreitol. Routinely, no EDTA was present in the samples; however, it was always checked whether identical protein patterns were obtained upon addition of EDTA (20mM) to the samples before electrophoresis. Electrophoresis (6h at 8mA/gel at 300C) was performed in the phosphate-buffered system described by ' Weber & Osborn (1969 Fairbanks et al. (1971) . After destaining, densitometric records were obtained by using a type 1 101M spectrophotometer equipped with a type 2602 scanning device (Eppendorf). The gels were scanned at 623 nm or 546 nm when stained for protein or carbohydrate respectively. Molecular weights were estimated from a linear semilogarithmic plot relating molecular weight to electrophoretic mobility by the BDH molecularweight markers (range 14 3000-71 500).
Protein determination. This was performed by measuring the A280 by using A " 11.6 for purified human Factor X (Di Scipio et al., 1977a) and A"0m 10 for all other proteins.
Lipid phosphorus determination. This was per-1980 formed after HCl04 combustion, as described by Bottcher et al. (196 1 (0.1 mg/ml), heparin (2 i.u./ml) and 10 mM-benzamidine hydrochloride. Solid BaCl2 (15 g/l) was then added gradually at 4°C under continuous stirring. After 30min the insoluble barium citrate was separated from the supernatant plasma by centrifugation (5 min at 5500 g). The precipitate was washed with one-third of the original volume of 0.15 M-BaCl2 and distilled water, and eluted with 0.33vol. of 0.15M-sodium citrate buffer (pH 7.5). Washing and eluting solutions always contained 6 mM-benzamidine, soyabean trypsin inhibitor (0.1 mg/ml) and Trasylol (5 kallikrein inhibitor units/ml). Eluted proteins were dialysed overnight against 25 vol. of 25 mM-sodium citrate buffer (pH 8.0) containing 3 mM-benzamidine, concentrated by ultrafiltration (PM 10 membrane, Amicon Europe B.V., Oosterhout, The Netherlands), and applied to a column (2.6cm x 12cm) of DEAE-Sephadex A-50, previously swollen and equilibrated with 30mM-sodium citrate/3 mM-benzamidine (pH 8.0, conductivity 7 inS). The column was washed with about 180ml of equilibration buffer, and proteins were eluted with a linear gradient of KCl in the same buffer (0-0.5 M; 2 x 800 ml). Factors II, IX and X are eluted at about 37mS, whereas Factor VII is eluted at about 25 inS. Fractions containing Factor X activity were pooled, dialysed against 1 mM-benzamidine/0. 1 MNaCl/0.02 M-sodium citrate/0.05 M-Tris/HCl, pH 7.4, and concentrated to about 20 ml. The Factor X concentrate was then applied to a column (2.6 cm x 26 cm) of heparin-Sepharose (type I) to remove Factor IX. Factor X and II activities pass through, whereas the Factor IX activity is retarded considerably (Bertina & Veltkamp, 1978) . Factor Xcontaining fractions were pooled and dialysed against 5 mM-KCl/lOmM-triethanolamine/HCl, pH 6.35. After the addition of CaCl2 (final concentration Vol. 185 3mM) the dialysis residue was applied to a column (1.6cm x 22cm) of heparin-Sepharose (type II) previously equilibrated in the same biuffer. Factor II activity passes through, whereas Factor X is eluted in a linear gradient of 5-500 mM-KCl (2 x 200 ml) at a conductivity of about 20 mS. Fractions containing Factor X activity were pooled, dialysed against 0.1 M-NaCl/0.05M-Tris/HCl, pH 7.5, and stored at -200C.
Preparation ofother coagulationfactors
Human Factor VII. This was prepared from the Factor-VII-containing fractions obtained after the DEAE-Sephadex gradient elution (see Factor X isolation (Bertina & Veltkamp, 1978) with about 4,ug of a Factor XIa preparation (0sterud & Rapaport, 1977) in the presence of CaCl2 (5 mM) for 24 h at room temperature in a plastic tube. Factor XIa was then removed by transferring the reaction mixture into a glass tube.
The Factor IXa prepared this way consists of a twochain molecule with an apparent mol.wt. of 47 000.
Phospholipid ('cephalin'). This was prepared from human brain as described by Milstone (1950) . The resulting phospholipid suspension was extracted twice in a chloroform/methanol/water system (6:3: 1, by vol.). Purified phospholipids were stored as stock solutions in chloroform at -200C under N2. For use in the experiments, liposomes were prepared by removing the solvent in a rotating evaporator and by dispersing the dry lipid film in 0.1 M-NaCl/0.05 M-Tris/HCl, pH 7.5 (0.2 ml/,umol of phosphorus) by vigorous mixing on a vortex-mixer for 1 min.
Results
Isolation ofFactor X Table 1 summarizes the isolation of human Factor X as described in the Experimental section. In steps 3, 4 and 5, Factor X is separated from Factors VII, IX and II respectively. The final preparation contained no detectable thrombin, Factor Xa, Factor VII or Factor IX activity; the presence of trace amounts of Factor II (<0.0025unit/unit of Factor X) cannot be excluded. For the specific activity of the final Factor X preparation two different values were obtained: (a) 46 units/mg by the onestage Factor X-coagulation assay, with Factor VII and thromboplastin as activator; (b) 130units/mg by two-stage amidolytic assay, with Russell's-viper venom as activator. The latter value, which could be confirmed by the electroimmunoassay for Factor X, is similar to the values obtained by Kosow (1976) and Di Scipio et al. (1977a) using a coagulation assay with Russell's-viper venom as activator; a specific activity of 130units/mg corresponds to a 9000-fold purification of Factor X when compared with pooled normal plasma. The reason for the low specific activity obtained in our coagulation assay might be that, owing to aggregation of purified Factor X, the initial rate of Factor X activation by Factor VII and thromboplastin is decreased compared with Factor X in normal plasma. On SDS/polyacrylamide-gel electrophoresis (see Fig. 1 ), purified Factor X migrates as a single band with an apparent mol.wt. of 72 000; after reduction, more than 95% of the protein appears in two bands of mol.wts. of 55000 and about 19000. A rabbit antibody prepared against the purified Factor X gave one precipitation arc against normal plasma, while no precipitation occurred against plasma of a patient with congenital Factor X deficiency (Factor X < 0.01 unit/ml). Activation ofFactor X by Russell's-viper venom Fig. 2(a) shows the development of amidolytic activity during the activation of Factor X by Russell's-viper venom in the presence of Ca2+.
Analysis of the incubation mixture by SDS/polyacrylamide-gel electrophoresis shows that, parallel to the appearance of amidolytic activity, a major band appeared with an apparent mol.wt. of 54000 (Fig.  2b) . A smaller band appeared that had a mol.wt. of 39000. After 5 h of incubation, a small additional band (mol.wt. 50000) became visible as a shoulder on the 54000-mol.wt. band (pattern D in Fig. 2b ). At this time, the conversion of Factor X to Factor Xa was nearly complete. This preparation was used as source of Factor Xa in the experiments described below. Pattern (E) in Fig. 2(b) shows that incubation of this preparation (still containing Ca2+) with phospholipid caused a nearly complete shift of the Factor Xa band from mol.wt. 54000 to 50000. After this incubation, 70% of the amidolytic activity was recovered. This indicates that the component with mol.wt. 50000 represents another form of Factor Xa.
Conversion ofFactor X by Factor Xa
To study possible feedback reactions of Factor Xa on Factor X during activation reactions, these two factors were incubated in the presence of Ca2+ and phospholipid. Fig. 3(a) shows the results of the amidolytic assays of samples from the incubation mixture. The assays for Factor Xa showed that no Vol. 185 amidolytic activity developed during the incubation. However, the assays for Factor X showed a sharp decrease in the concentration of activatable Factor X. Fig. 3(b) shows the analysis of samples from the same incubation mixture by SDS/polyacrylamidegel electrophoresis. Factor X was initially converted to a product with an apparent mol.wt. of 59000 (Fig. 3b, pattern B) . On further incubation, bands appeared with mol.wts. of 39000, 24000 and 16 000. After incubation for 22 h, no intact Factor X was present anymore (Fig. 3b, pattern D) .
Essentially no degradation of Factor X could be detected, either when Factor Xa, phospholipid or Ca2+ were omitted from the incubation mixture or when soya-bean trypsin inhibitor, an inhibitor of Factor Xa, was included in the complete incubation mixture. Addition of hirudin, an inhibitor of thrombin, did not influence the degradation of Factor X; this excludes the possibility that the conversions observed are due to thrombin, which might have been formed from trace amounts of Factor II contaminating the Factor X preparation. Replacement of the cephalin by a mixture of pure phosphatidylcholine and phosphatidylserine (molar ratio 1:1) did not in- These results demonstrate that Factor Xa can convert Factor X to components with mol.wts. of 59000 and 39000, and to smaller products, all without amidolytic activity towards the substrate S-2222. Furthermore, the assays for Factor X indicate that none of these products, including the 59 000-mol.wt. component, can be converted to an active form by the Russell's-viper venom used in the assay (see Fig. 3b, pattern D) . Activation of Factor X in the presence ofphospholipid
In the experiments described above, the conversions of Factor X by an activator, Russell's-viper venom, and by the product of the activation reaction, Factor Xa, have been studied separately. In the following experiment, these two processes were combined by incubating Factor X with Russell's-viper venom in the presence of Ca2+ and phospholipid. Fig. 4 shows the analysis by SDS/polyacrylamide-gel electrophoresis of the reaction mixture after 30min of incubation. Pattern (A) shows that the major products formed from Factor X (mol.wt. 72000) are the components with mol.wts. 54000 and 50000, which have been shown to represent two forms of Factor Xa (cf. Fig. 2b , patterns D and E). The other products, the components with mol.wts. 59000, 39000, 24000 and 16000, have been shown to represent inactive products (cf. Fig. 3b) . Pattern (C) shows that, after reduction, a comparable electrophoretic pattern is obtained. The components with mol.wts. 72000, 59000, 54000 and 50000 are located now at positions corresponding to mol.wts. of 55 000, 41 000, 35 000 and 31 000 respectively. In all these cases the difference between the molecular weights of the non-reduced and reduced molecules is about 19 000, the molecular weight of the light chain (see Fig. 1, pattern B of Factor X to Factor Xa most of the carbohydrate is lost, whereas upon formation of the 59000-mol.wt. component most of the carbohydrate is conserved. In human Factor X the major portion of the carbohydrate is known to be located on the Nterminal portion of the heavy chain (Di Scipio et al., 1977b) . Therefore formation of the relatively carbohydrate-rich 59 000-mol.wt. component from Factor X can be explained by the release of a carbohydrate-poor peptide with a calculated mol.wt. of 13000 from the C-terminal region of the heavy chain. In parallel with the formation of the 59000-mol.wt. component, the amidolytic activity generated in the Factor X assay decreases (see Fig. 3a ). This suggests that the released 13000-mol.wt. peptide contains a part of the Factor X molecule that is essential for the catalytic activity. A peptide of Vol. 185 mol.wt. 13 000 consists of about 100 amino acids. As 0.8 1.0 is known from the primary structure of bovine Factor X , the active-site serine is the 75th amino acid, as counted from the C-terminus. If the same is assumed to be true for human Factor X, the 13000-mol.wt. peptide would contain the activesite serine residue. This hypothesis can be tested by labelling Factor X in its active-site serine and by analysing the degradation products of this Factor X t(A)
on the presence of the labelled serine residue.
Degradation of[3HIDip-Factor X by Factor Xa Figs. 5(a) and 5(b) show the analysis by SDS/ polyacrylamide-gel electrophoresis of human Factor X after incubation with [3H]Dip-F. In preliminary experiments performed with unlabelled Dip-F, it was found that under the experimental conditions described about 25% of the amidolytic activity in the Factor X assay is lost, whereas in a control incubation in the absence of Dip-F all activity is recovered. This confirms the incorporation of Dip into the active-site serine residue of the zymogen form of human Factor X, as described for bovine Factor X by Kerr et al. (1978) . Comparison of the protein pattern ( Fig. 5a ) with the distribution of the radioactivity (Fig. 5b) Scipio et al., 1977b) , this implies an incorporation of 0.22mol of Dip/mol of Factor X. As shown in Fig. 5(c) , incubation of [3HIDip-Factor X with Factor Xa in the presence of Ca2+ and phospholipid resulted in the appearance of two new protein bands, corresponding to a peptide of mol.wt. 13000 and to the heavy chain of the 59000-mol.wt. component (cf. Fig. 3b,  pattern B) . About 80% of the radioactivity present in these products is associated with the 13 000-mol.wt. peptide (Fig. Sd) . This demonstrates that Factor Xa cleaves the heavy chain of Factor X, releasing a peptide of mol.wt. 13 000, which contains the active-site serine residue. [3H]Dip-Factor X was prepared by incubation of 450,l of Factor X (880,ug/ml in 0.1 M-NaCl/0.05 M-Tris/HCl, pH 7.5) with 4.5 ,1 of 1 M-Dip-F (in propan-2-ol) and lOO,u of [3H1-Dip-F (0.5 mCi; 0. 17,umol in propylene glycol) at 250C. After 24h, 450,1 of 0.1 M-NaCI/0.05M-Tris/HCl, pH 7.5, was added; this mixture was dialysed exhaustively against the same buffer. Reduced samples (lOO,l) from this preparation (containing 20mM-EDTA) were analysed by SDS/polyacrylamide-gel electrophoresis on 10% (w/v) gels. The gels were stained for protein (a) or sliced and analysed for radioactivity as described in the Experimental section (b). In a final volume of 350,ul, 90pg of 13H]-DipFactor X (specific radioactivity 9.2 x IO' d.p.m./mg) was incubated with Factor Xa (3.5,ug) in the presence of phospholipid (cephalin, O.lumol of phosphorus) and CaCl2 (10mM) at 370C. After 4h of incubation, 140,1 from the reaction mixture was analysed for protein (c) and radioactivity (d) as described above.
tor X was activated by the extrinsic and intrinsic activator. In these experiments low concentrations of activating proteins were used, both to prevent interference with the Factor X-derived bands on the SDS/polyacrylamide-gel patterns, and to enable detection of the initial events. Fig. 6 shows the activation of Factor X by Factor VII and thromboplastin in the presence of Ca2+ (the extrinsic activator). In preliminary experiments, the rate of Factor Xa formation was found to depend on the Factor VII concentration, whereas no Factor Xa was formed when either Factor VII or thromboplastin were omitted. Fig. 6(b) shows the analysis of samples from the incubation mixture by SDS/polyacrylamide-gel electrophoresis. The component with apparent mol.wt. 55000 (see pattern B) corresponds to the form of Factor Xa with mol.wt. 54000 (cf. Figs. 2b and 4) . The conversion of this form to the lower-molecular-weight form in the presence of phospholipid was also observed in the present experiment: after 1 h a small band was visible at mol.wt. 51000, which became more intense than the 55 000-mol.wt. band on further incubation.
In agreement with the relatively low intensity of these two bands, only low amidolytic activity developed during the experiment (Fig. 6a) . After 3h of incubation, the rate of development of Factor Xa activity was decreased, possibly because of inactivation of activated Factor VII by Factor Xa, as has been reported by Radcliffe & Nemerson (1975) . At the same time, the electrophoretic pattern (Fig. 6b,  pattern D) shows an additional band at mol.wt. 60000, corresponding to the inactivatable 59000-mol.wt. component in Figs. 3(b) , 4 and 5. Also the remaining bands, at mol.wts. 40000 and 18000 have been observed in the previous experiments. Fig. 7 shows the activation of Factor X by Factor IXa and Factor VIII in the presence of Ca2+ and phospholipid (the intrinsic activator). In preliminary experiments, no detectable Factor Xa was formed in the absence of Ca2+, phospholipid or Factor IXa, whereas omission of Factor VIII (not previously activated by thrombin) had only little effect on the initial rates of Factor Xa production and Factor X degradation. Fig. 7(a) decreased again after 2 h of incubation. The assays for Factor X, however, demonstrated a sharply decreasing Factor X concentration during the incubation, comparable with that shown in Fig. 3(a) . After 6 h the amidolytic activities in the Factor X and Factor Xa assays were equal, suggesting that no Factor X was left for activation by the Russell's-viper venom used in the Factor X assay. Similar results were obtained from the SDS/polyacrylamide-gel patterns (Fig. 7b) . Parallel to the decreasing activity in the Factor X assays, the Factor X band, at mol.wt. 72000, moved to two major bands at mol.wts. 60000 and 40000 (cf. Fig. 3b ). When Factor Xa activity was maximal (after 1 and 2 h of incubation), the gel patterns (C and D) show a minor band at mol.wt. 51000, which suggests that this band represents the 50000-mol.wt. form of Factor Xa (cf. Fig. 2b , pattern E). As in the experiment described in Fig. 3 , at the end of the incubation all protein had accumulated in three major bands, at mol.wts. of 40 000, 24 000 and 17 000.
These results show that when human Factor X is activated by its physiological activators, essentially the same products are formed as on activation by Vol. 185
Russell's-viper venom in the presence of Ca2+ and phospholipid (Fig. 4) . This suggests that Factor X is converted to Factor Xa by the physiological activators in the same way as by Russell's-viper venom, whereas the other, inactive, products are formed by the subsequent action of the product of the activation reaction, Factor Xa.
Discussion
By use of the electrophoresis system described in the Experimental section, a mol.wt. of 72000 was found for human Factor X. However, it has to be realized that molecular-weight values strongly depend on the method of determination. Molecularweight values for human Factor X have been reported of between 59000, based on amino acid and carbohydrate composition (Di Scipio et al., 1977b) , and 75000, as found by Kosow (1976) using SDS/polyacrylamide-gel electrophoresis. In the present study, Factor X and the Factor Xderived components have been characterized according to their apparent molecular weights. In our experiments, Factor X was converted to active forms of mol.wts. 54000 and 50000, to inactive components of mol.wts. 59000 and 39000, and to smaller fragments. These conversions have been shown to be caused by proteolytic cleavages at three sites on the heavy chain (Fig. 4) . The location of these sites, which we called the a -, f,-and y-sites, is shown in Fig. 8 . The first two sites have been recognized earlier in bovine Factor X (Fujikawa et al., , 1974 Jesty et al., , 1975 and human Factor X (Di Scipio et al., 1977b) , and have been shown to be located on the N-terminal region (the a -site) and the C-terminal region (the fl-site) of the heavy chain. The cleavage of Factor X at the third site, the y-site, has not been reported earlier.
The location of this site on the C-terminal region of the heavy chain has been demonstrated in two ways: (a) the fragment released does not contain major amounts of carbohydrate (see Fig. 4 ), which are known to be located on the N-terminal region of the heavy chain (Di Scipio et al., 1977b) , and (b) the fragment released contains the active-site serine residue (see Fig. 5 ), which is known to be located on the C-terminal region of the heavy chain (Titani et al., 1972 Di Scipio et al., 1977b) .
According to our nomenclature proposal (see Fig.  8 ), the various active (Xa) and inactive (X) molecular forms are indicated with a, fl and/or y as (a) prefix(es), according to the proteolytic cleavage(s) by which they are formed. In our model, the first active form of factor X, with mol.wt. 54000, is formed by proteolytic cleavage of the a-site in intact Factor X by Russell's-viper venom or the physiological activators (Figs. 2b, 4 and 6b) . The products of this cleavage are Factor aXa and an Nterminal glycopeptide, fragment-a (F a). In the presence of phospholipid, Factor aXa is converted to a second active form, with mol.wt. 50000, by the cleavage of the fl-site by Factor Xa (Figs. 2b, 4 , 6b and 7b), giving rise to Factor a,BXa and a C-terminal peptide, fragment-fl (F/I). The conversion of Factor X to the inactivatable component of mol.wt. 59000 (Figs. 3b, 4 (Fig. 3b, patterns C and D; Fig. 7b , pattern E) is negative on staining for carbohydrate (Fig. 4) (Segrest et al., 1971) , it can be expected that for the glycopeptide Fa a higher molecular weight is found than the value of 18000 that can be calculated as the difference in molecular weight between factor X and factor aXa. Therefore the 24 000-mol.wt. band may be attributed to fragment Fa. The other fragments migrate in the front in our electrophoresis system (7.5% (w/v) polyacrylamide gels), and are found in the 16000-mol.wt. position. The calculated mol.wt. of 13000 for fragment Fy could be confirmed by using 10% (w/v) polyacrylamide gels (Fig. 5) Fujikawa et al. (1974) and Di Scipio et al. (1977b) for bovine and human Factor X respectively. According to the proposal of Jesty et al. ( , 1975 for bovine Factor X, these components are called Intermediate-1, a-Xa and fI-Xa.
These authors also identified an additional component, Intermediate-2, which was formed in a relatively insignificant pathway by the cleavage of the heavy chain at a third site. Because this site was identified between the a-site and the N-terminus, it is different from the y-site shown in Fig. 8 .
In the bovine system, Factor a,fXa can also be formed in a pathway other than that described above: Factor X is cleaved by Factor Xa at the f,-site, and the resulting Factor ,6X is converted to Factor afiXa by the subsequent cleavage of the a-site by an activator or by Factor Xa (Fujikawa et a!., 1974; . In the human system, however, the major product of the action of Factor Xa on Factor X is Factor yX, which, because it lacks the active-site serine residue, cannot be converted to an active product by the subsequent cleavage of the a-site. Preliminary experiments on the question why the action of Factor Xa on Factor X is different in the human and the bovine system suggest a structural difference between human and bovine Factor X rather than a difference in substrate specificity between human and bovine Factor Xa.
Recent kinetic studies have shown that the Km of Factor X for its activation by the extrinsic activator (Silverberg et al., 1977) and the intrinsic activator (Brown et al., 1978 ) is higher than the plasma concentration. With respect to this finding, the cleavage of Factor X at the y-site by Factor Xa might be a regulatory principle. Theoretically, the formation of Factor yX can then influence the rate of Factor Xa formation both by decreasing the Factor X concentration and by introducing competition between Factor yX and Factor X for cleavage of the a-site by the intrinsic and extrinsic activator.
